Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not
Source: SeekingAlpha
2026-02-20 07:30:47 ET
In January, I rated Corcept Therapeutics ( CORT ) a Hold , citing severe binary risk of its looming patent appeal against Teva Teva Pharmaceutical Industries ( TEVA ). On February 19th, the US Court of Appeals for the Federal Circuit affirmed the lower court's ruling, siding with Teva. As a consequence, a generic version of Corcept's drug Korlym will soon be on the market, calling into question all of Corcept's sales....
Read the full article on Seeking Alpha
For further details see:
Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
0.21% G/L:
$228.2209 Last:
2,045,501 Volume:
$226.05 Open:
ABBV Latest News
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
